Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease.

Kotecha D, Flather MD, Atar D, Collins P, Pepper J, Jenkins E, Reid CM, Eccleston D; Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study.

BMC Med. 2019 Apr 3;17(1):72. doi: 10.1186/s12916-019-1306-9.

2.

Reply: An Incomplete Story.

Cleland JGF, Flather MD, Altman DG, Kotecha D; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2018 Jan 2;71(1):105. doi: 10.1016/j.jacc.2017.10.078. No abstract available.

3.

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.

Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group.

Eur Heart J. 2018 Jan 1;39(1):26-35. doi: 10.1093/eurheartj/ehx564.

4.

Determinants of Length of Stay Following Total Anterior Circulatory Stroke.

Curtain JP, Yu M, Clark AB, Gollop ND, Bettencourt-Silva JH, Metcalf AK, Bowles KM, Flather MD, Potter JF, Myint PK.

Geriatrics (Basel). 2017 Aug 4;2(3). pii: E26. doi: 10.3390/geriatrics2030026.

5.

Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease.

Vedin O, Hagström E, Östlund O, Avezum A, Budaj A, Flather MD, Harrington RA, Koenig W, Soffer J, Siegbahn A, Steg PG, Stewart RAH, Wallentin L, White HD, Held C; STABILITY Investigators.

Int J Cardiol. 2017 Oct 15;245:271-276. doi: 10.1016/j.ijcard.2017.07.036. Epub 2017 Jul 17.

PMID:
28735759
6.

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.

Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.

7.

Inflammatory Differences in Plaque Erosion and Rupture in Patients With ST-Segment Elevation Myocardial Infarction.

Chandran S, Watkins J, Abdul-Aziz A, Shafat M, Calvert PA, Bowles KM, Flather MD, Rushworth SA, Ryding AD.

J Am Heart Assoc. 2017 May 3;6(5). pii: e005868. doi: 10.1161/JAHA.117.005868.

8.

Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.

Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Böhm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson Å, Kjekshus J, Cleland JGF; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2017 Jun 20;69(24):2885-2896. doi: 10.1016/j.jacc.2017.04.001. Epub 2017 Apr 30. Review.

9.

Observational Versus Randomized: Sliding Toward Nonevidence-Based Medicine.

Kotecha D, Altman DG, Rosano G, Flather MD.

JACC Heart Fail. 2017 May;5(5):395-396. doi: 10.1016/j.jchf.2017.02.013. No abstract available.

10.

A 6-Point TACS Score Predicts In-Hospital Mortality Following Total Anterior Circulation Stroke.

Wood AD, Gollop ND, Bettencourt-Silva JH, Clark AB, Metcalf AK, Bowles KM, Flather MD, Potter JF, Myint PK.

J Clin Neurol. 2016 Oct;12(4):407-413. doi: 10.3988/jcn.2016.12.4.407.

11.

Authors' reply to Cunningham and Messerli and colleagues.

Kotecha D, Altman DG, Collins PD, Flather MD.

BMJ. 2016 Jun 7;353:i3141. doi: 10.1136/bmj.i3141. No abstract available.

PMID:
27268202
12.

Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis.

Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJ, Cleland JG, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GY, van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

BMJ. 2016 Apr 20;353:i1855. doi: 10.1136/bmj.i1855. Review.

13.

Understanding Mechanisms of Action of Beta-Blockers in Heart Failure With Reduced and Preserved Ejection Fraction.

Flather MD, Gollop ND.

JACC Heart Fail. 2016 Feb;4(2):150-151. doi: 10.1016/j.jchf.2015.12.009. No abstract available.

PMID:
26823116
14.

Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.

Pitcher A, Emberson J, Lacro RV, Sleeper LA, Stylianou M, Mahony L, Pearson GD, Groenink M, Mulder BJ, Zwinderman AH, De Backer J, De Paepe AM, Arbustini E, Erdem G, Jin XY, Flather MD, Mullen MJ, Child AH, Forteza A, Evangelista A, Chiu HH, Wu MH, Sandor G, Bhatt AB, Creager MA, Devereux RB, Loeys B, Forfar JC, Neubauer S, Watkins H, Boileau C, Jondeau G, Dietz HC, Baigent C.

Am Heart J. 2015 May;169(5):605-12. doi: 10.1016/j.ahj.2015.01.011. Epub 2015 Feb 12.

15.

β blockers in patients with heart failure and atrial fibrillation - Authors' reply.

Kotecha D, Altman DG, Manzano L, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

Lancet. 2015 Apr 25;385(9978):1618-9. doi: 10.1016/S0140-6736(15)60789-9. No abstract available.

PMID:
25943812
16.

Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.

Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

Lancet. 2014 Dec 20;384(9961):2235-43. doi: 10.1016/S0140-6736(14)61373-8. Epub 2014 Sep 2.

PMID:
25193873
17.

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.

Morton AC, Rothman AM, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS, Fox K, Foley C, Banya W, Wang D, Flather MD, Crossman DC.

Eur Heart J. 2015 Feb 7;36(6):377-84. doi: 10.1093/eurheartj/ehu272. Epub 2014 Jul 30.

18.

Effects of nebivolol on biomarkers in elderly patients with heart failure.

Taneja AK, Gaze D, Coats AJ, Dumitrascu D, Spinarova L, Collinson P, Roughton M, Flather MD; SENIORS Investigators.

Int J Cardiol. 2014 Aug 1;175(2):253-60. doi: 10.1016/j.ijcard.2014.05.018. Epub 2014 May 17.

PMID:
24877590
19.

Darapladib for preventing ischemic events in stable coronary heart disease.

STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L.

N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30.

20.

A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.

Mullen MJ, Flather MD, Jin XY, Newman WG, Erdem G, Gaze D, Valencia O, Banya W, Foley CE, Child A.

Trials. 2013 Dec 1;14:408. doi: 10.1186/1745-6215-14-408.

21.

Comparison of drug-eluting and bare-metal stents in patients with diabetes undergoing primary percutaneous coronary intervention: what is the evidence?

Gollop ND, Henderson DB, Flather MD.

Interact Cardiovasc Thorac Surg. 2014 Jan;18(1):112-6. doi: 10.1093/icvts/ivt454. Epub 2013 Oct 20. Review.

22.

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S.

Circulation. 2013 Jul 16;128(3):237-43. doi: 10.1161/CIRCULATIONAHA.112.001139. Epub 2013 Jun 14.

PMID:
23770747
23.

Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design.

Kotecha D, Manzano L, Altman DG, Krum H, Erdem G, Williams N, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

Syst Rev. 2013 Jan 18;2:7. doi: 10.1186/2046-4053-2-7.

24.

Rates and causes of death from non-ST elevation acute coronary syndromes: ten year follow-up of the PRAIS-UK registry.

Erdem G, Bakhai A, Taneja AK, Collinson J, Banya W, Flather MD.

Int J Cardiol. 2013 Sep 20;168(1):490-4. doi: 10.1016/j.ijcard.2012.09.160. Epub 2012 Nov 6.

PMID:
23138011
25.

Role of multidetector computed tomography in the diagnosis and management of patients attending the rapid access chest pain clinic, The Scottish computed tomography of the heart (SCOT-HEART) trial: study protocol for randomized controlled trial.

Newby DE, Williams MC, Flapan AD, Forbes JF, Hargreaves AD, Leslie SJ, Lewis SC, McKillop G, McLean S, Reid JH, Sprat JC, Uren NG, van Beek EJ, Boon NA, Clark L, Craig P, Flather MD, McCormack C, Roditi G, Timmis AD, Krishan A, Donaldson G, Fotheringham M, Hall FJ, Neary P, Cram L, Perkins S, Taylor F, Eteiba H, Rae AP, Robb K, Barrie D, Bissett K, Dawson A, Dundas S, Fogarty Y, Ramkumar PG, Houston GJ, Letham D, O'Neill L, Pringle SD, Ritchie V, Sudarshan T, Weir-McCall J, Cormack A, Findlay IN, Hood S, Murphy C, Peat E, Allen B, Baird A, Bertram D, Brian D, Cowan A, Cruden NL, Dweck MR, Flint L, Fyfe S, Keanie C, MacGillivray TJ, Maclachlan DS, MacLeod M, Mirsadraee S, Morrison A, Mills NL, Minns FC, Phillips A, Queripel LJ, Weir NW, Bett F, Divers F, Fairley K, Jacob AJ, Keegan E, White T, Gemmill J, Henry M, McGowan J, Dinnel L, Francis CM, Sandeman D, Yerramasu A, Berry C, Boylan H, Brown A, Duffy K, Frood A, Johnstone J, Lanaghan K, MacDuff R, MacLeod M, McGlynn D, McMillan N, Murdoch L, Noble C, Paterson V, Steedman T, Tzemos N.

Trials. 2012 Oct 4;13:184. doi: 10.1186/1745-6215-13-184.

26.

Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT study.

Mackness B, Marsillach J, Elkeles RS, Godsland IF, Feher MD, Rubens MB, Flather MD, Humphries SE, Cooper J, Mackness M.

Dis Markers. 2012;33(2):101-12. doi: 10.3233/DMA-2012-0910.

27.

Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS.

Mulder BA, van Veldhuisen DJ, Crijns HJ, Böhm M, Cohen-Solal A, Babalis D, Roughton M, Flather MD, Coats AJ, Van Gelder IC.

Eur J Heart Fail. 2012 Oct;14(10):1171-8. Epub 2012 Jul 4.

28.

Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program.

O'Donoghue ML, Bhatt DL, Flather MD, Goto S, Angiolillo DJ, Goodman SG, Zeymer U, Aylward PE, Montalescot G, Ziecina R, Kobayashi H, Ren F, Wiviott SD.

J Thromb Thrombolysis. 2012 Jul;34(1):36-43. doi: 10.1007/s11239-012-0750-6.

PMID:
22653705
29.

Radial artery pulse wave analysis for non-invasive assessment of coronary artery disease.

Kotecha D, New G, Collins P, Eccleston D, Krum H, Pepper J, Flather MD.

Int J Cardiol. 2013 Aug 10;167(3):917-24. doi: 10.1016/j.ijcard.2012.03.098. Epub 2012 Apr 4.

PMID:
22483418
30.

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.

Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ; CHARISMA Investigators.

Eur Heart J. 2012 Sep;33(17):2143-50. Epub 2012 Mar 26.

PMID:
22450429
31.

Five-minute heart rate variability can predict obstructive angiographic coronary disease.

Kotecha D, New G, Flather MD, Eccleston D, Pepper J, Krum H.

Heart. 2012 Mar;98(5):395-401. doi: 10.1136/heartjnl-2011-300033. Epub 2011 Nov 25.

PMID:
22121069
32.

Prevalence and outcome of subclinical rheumatic heart disease in India: the RHEUMATIC (Rheumatic Heart Echo Utilisation and Monitoring Actuarial Trends in Indian Children) study.

Saxena A, Ramakrishnan S, Roy A, Seth S, Krishnan A, Misra P, Kalaivani M, Bhargava B, Flather MD, Poole-Wilson PP.

Heart. 2011 Dec;97(24):2018-22. doi: 10.1136/heartjnl-2011-300792. Epub 2011 Nov 10.

PMID:
22076022
33.

Cluster-randomized trial to evaluate the effects of a quality improvement program on management of non-ST-elevation acute coronary syndromes: The European Quality Improvement Programme for Acute Coronary Syndromes (EQUIP-ACS).

Flather MD, Babalis D, Booth J, Bardaji A, Machecourt J, Opolski G, Ottani F, Bueno H, Banya W, Brady AR, Bojestig M, Lindahl B.

Am Heart J. 2011 Oct;162(4):700-707.e1. doi: 10.1016/j.ahj.2011.07.027.

PMID:
21982663
34.

Assessment of data quality in an international multi-centre randomised trial of coronary artery surgery.

Krzych LJ, Lees B, Nugara F, Banya W, Bochenek A, Cook J, Taggart D, Flather MD.

Trials. 2011 Sep 26;12:212. doi: 10.1186/1745-6215-12-212.

35.

Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials.

Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A, Flather MD.

Am Heart J. 2011 May;161(5):822-831.e2. doi: 10.1016/j.ahj.2011.02.013. Review.

PMID:
21570510
36.

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.

O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, Angiolillo DJ, Goto S, Montalescot G, Zeymer U, Aylward PE, Guetta V, Dudek D, Ziecina R, Contant CF, Flather MD; LANCELOT-ACS Investigators.

Circulation. 2011 May 3;123(17):1843-53. doi: 10.1161/CIRCULATIONAHA.110.000786. Epub 2011 Apr 18.

PMID:
21502577
37.

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.

Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL; LANCELOT-CAD Investigators.

Circulation. 2011 May 3;123(17):1854-63. doi: 10.1161/CIRCULATIONAHA.110.001404. Epub 2011 Apr 18.

PMID:
21502571
38.

Predictors of clinical outcomes in elderly patients with heart failure.

Manzano L, Babalis D, Roughton M, Shibata M, Anker SD, Ghio S, van Veldhuisen DJ, Cohen-Solal A, Coats AJ, Poole-Wilson PP, Flather MD; SENIORS Investigators.

Eur J Heart Fail. 2011 May;13(5):528-36. doi: 10.1093/eurjhf/hfr030. Epub 2011 Mar 30.

39.

β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure.

Ambrosio G, Flather MD, Böhm M, Cohen-Solal A, Murrone A, Mascagni F, Spinucci G, Conti MG, van Veldhuisen DJ, Tavazzi L, Coats AJ.

Heart. 2011 Feb;97(3):209-14. doi: 10.1136/hrt.2010.207365. Epub 2010 Dec 6.

PMID:
21138861
40.

Can protein biomarkers provide an index of coronary artery calcification in patients with Type 2 diabetes?

Godsland IF, Pavitt D, Okoturo O, Edwards RJ, Rubens MB, Feher MD, Flather MD, Elkeles RS; PREDICT Study Group.

Atherosclerosis. 2010 Dec;213(2):570-2. doi: 10.1016/j.atherosclerosis.2010.09.002. Epub 2010 Sep 15.

PMID:
20880528
41.

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.

Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators.

Eur Heart J. 2010 Nov;31(21):2601-13. doi: 10.1093/eurheartj/ehq320. Epub 2010 Aug 30.

42.

Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a comparative literature review.

Barth JH, Jackson BM, Farrin AJ, Efthymiou M, Worthy G, Copeland J, Bailey KM, Romaine SP, Balmforth AJ, McCormack T, Whitehead A, Flather MD, Nixon J, Hall AS; SPACE ROCKET Trial Group.

Clin Chem. 2010 Oct;56(10):1592-8. doi: 10.1373/clinchem.2010.145631. Epub 2010 Aug 20. Review.

43.

Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]).

de Boer RA, Doehner W, van der Horst IC, Anker SD, Babalis D, Roughton M, Coats AJ, Flather MD, van Veldhuisen DJ; SENIORS Investigators.

Am J Cardiol. 2010 Jul 1;106(1):78-86.e1. doi: 10.1016/j.amjcard.2010.02.018.

PMID:
20609652
44.

Role of dual antiplatelet therapy in symptomatic patients with established vascular disease: putting the CHARISMA trial into therapeutic perspective.

Boden WE, Flather MD, Bhatt DL.

Cardiovasc Drugs Ther. 2010 Jun;24(3):207-16. doi: 10.1007/s10557-010-6245-9.

PMID:
20593231
45.

What goes into a major acute coronary syndrome trial and what will future trials look like?

Erdem G, Geisler T, Flather MD.

Curr Cardiol Rep. 2010 Jul;12(4):348-55. doi: 10.1007/s11886-010-0119-4. Review.

PMID:
20496125
46.

Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.

Bailey KM, Romaine SP, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, McCormack T, Whitehead A, Flather MD, Samani NJ, Nixon J, Hall AS, Balmforth AJ; SPACE ROCKET Trial Group.

Circ Cardiovasc Genet. 2010 Jun;3(3):276-85. doi: 10.1161/CIRCGENETICS.109.898502. Epub 2010 Mar 5.

PMID:
20207952
47.

Improving the management of non-ST elevation acute coronary syndromes: systematic evaluation of a quality improvement programme European QUality Improvement Programme for Acute Coronary Syndrome: the EQUIP-ACS project protocol and design.

Flather MD, Booth J, Babalis D, Bueno H, Steg PG, Opolski G, Ottani F, Machecourt J, Bardaji A, Bojestig M, Brady AR, Lindahl B.

Trials. 2010 Jan 14;11:5. doi: 10.1186/1745-6215-11-5.

48.

A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial.

Hall AS, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, Bailey KM, Romaine SP, Balmforth AJ, McCormack T, Whitehead A, Flather MD, Nixon J; SPACE ROCKET Trial Group.

Eur J Cardiovasc Prev Rehabil. 2009 Dec;16(6):712-21. doi: 10.1097/HJR.0b013e3283316ce8.

PMID:
19745745
49.

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).

van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD; SENIORS Investigators.

J Am Coll Cardiol. 2009 Jun 9;53(23):2150-8. doi: 10.1016/j.jacc.2009.02.046.

50.

Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study.

Elkeles RS, Godsland IF, Feher MD, Rubens MB, Roughton M, Nugara F, Humphries SE, Richmond W, Flather MD; PREDICT Study Group.

Eur Heart J. 2008 Sep;29(18):2244-51. doi: 10.1093/eurheartj/ehn279. Epub 2008 Jun 23.

Supplemental Content

Loading ...
Support Center